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2752Objective: A proportion of patients experience a decrease in left ventricular (LV) ejection fraction (EF) after
mitral valve repair; however, predictors and long-term consequences remain unclear.
Methods:A study of 1705 patients with severe, degenerative mitral valve regurgitation and normal preoperative
EF (>60%) undergoing mitral valve repair from 1993 to 2012 was performed. Multivariate logistic regression
and Cox proportional hazards models were used to determine the predictors of early postoperative LV
dysfunction (EF<50%) and long-term survival, respectively.
Results: Postoperative outcomeswere comparable between patients; however, thosewith an EF of<50% (n¼ 314,
18.4%) had significantly greater enlargement in systolic dimension (left ventricular end-systolic diameter,0.6 vs
4.3 mm; P<.001) and decrease in right ventricular systolic pressure (2.7 vs7.8 mmHg; P<.001) immediately
after repair. On longitudinal follow-up, early LV impairment persisted, with EF recovering to preoperative levels
(>60%) in only one third of patients with postrepair EF<50% versus two thirds of those with an EF of 50%
(P<.001).Theoverall survival at 5, 10, and15years offollow-upwas95%, 85%, and70.8%, respectively.Although
early postoperativeEF<50%was not a significant determinant of late survival, when adjusting for older age (hazard
ratio [HR], 1.09), hypertension (HR, 1.38), NewYork Heart Association class III or IV (HR, 1.71), and preoperative
atrial fibrillation (HR, 2.33), postoperativeEF<40% conferred a 70% increase in the hazard of late death (HR, 1.74;
95% confidence interval, 1.03-2.92;P¼ .037).Apreoperative right ventricular systolic pressure>49mmHgand left
ventricular end-systolic diameter>36 mm were independently associated with a 4.4- and 6.5-fold increased risk of
developing a postoperative EF<40% (P<.001, for both).
Conclusions: De novo postoperative LV dysfunction is not uncommon in patients with ‘‘normal’’ preoperative
EF undergoing mitral valve repair. LV dysfunction can persist, impairing recovery of LV size, function, and sur-
vival. The consideration of mitral repair before the onset of excessive LV dilation or pulmonary hypertension,
even in those with preserved EF, seems warranted. (J Thorac Cardiovasc Surg 2014;148:2752-62)Although mitral valve repair is the only safe and effective
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The Journal of Thoracic and Cardiovascular Survalve regurgitation (MR), an international debate persists
regarding the need for, and timing of, ‘‘early’’ surgical
intervention.1-3 According to the latest American College
of Cardiology/American Heart Association guidelines,4 in
the absence of class I indications for surgical correction,
asymptomatic patients with normal left ventricular
(LV) function (ejection fraction [EF]> 60% and LV end-
systolic diameter [LVESD] 40 mm) are only offered early
repair as a class IIa recommendation.
Because LV dysfunction assessed by echocardiography is
often underestimated in patients with severe MR,5 reliance
on EF alone can be unreliable and delay referral for surgical
correction. Even in the presence of ‘‘normal’’ LV function,
chronic volume overload caused by severe MR can lead to
adverse consequences, such as atrial fibrillation, pulmonary
hypertension, and early postoperative LV dysfunction—all of
which can affect long-term survival.6,7 While the aim of
‘‘early surgery’’ is to prevent these sequelae and improve
patient prognosis, the predictors of both latent LV
dysfunction and the onset of guideline-based triggers in pa-
tientswith ‘‘normal’’ preoperativeLV function remain unclear.gery c December 2014
Abbreviations and Acronyms
CI ¼ confidence interval
EF ¼ ejection fraction
HR ¼ hazard ratio
LV ¼ left ventricular
LVESD ¼ LV end-systolic diameter
MR ¼ mitral valve regurgitation
OR ¼ odds ratio
RVSP ¼ right ventricular systolic pressure
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C
DThe ability to ascertain the ideal timing for mitral valve
repair to optimize survival and minimize morbidity pivots
on the a priori assumption that, in the absence of symptoms,
both the extent to which LVEF will be altered early after
mitral valve repair surgery8 and the exact subset of patients
with ‘‘normal’’ EF who are at risk of developing severe LV
dysfunction is predictable on an individual basis.9 A recent
report10 suggested that preoperative pulmonary hyper-
tension, atrial fibrillation, and increased LVESD,10 all
predicted an increased risk of postoperative LV dysfunction
after mitral valve repair. However, it is important to note
that this and other populations studied to date have included
patients with evidence of preoperative LV dysfunction
(classically LVEF<50%)11 before surgery. Whether these
findings are relevant in those with ‘‘normal’’ preoperative
EF is unknown. Because of this knowledge gap, our intent
was to study a population of patients with echocardiograph-
ically confirmed ‘‘normal’’ LVEF before isolated degenera-
tive mitral valve repair in the absence of ischemic disease to
(1) elucidate the frequency and predictors of an early
decline in LV systolic function, (2) analyze the timing
and extent of reverse LV remodeling, and (3) delineate a
quantitative threshold for early postoperative LVEF that
might influence long term survival.
METHODS
Study Subjects
The Mayo Clinic institutional review board approved the present study.
From January 1, 1993 to June 30, 2012, 5258 patients underwent
conventional open or minimally invasive mitral valve repair for
degenerative MR (ie, myxomatous disease or fibroelastic deficiency) at
Mayo Clinic Rochester. Our investigation was limited to patients with
preoperative echocardiographic evidence of normal LVEF (>60%). Those
with concomitant tricuspid valve repair, patent foramen ovale closure, or
surgery for atrial fibrillation were eligible for inclusion. The exclusion
criteria were concomitant coronary artery bypass grafting, a history of
myocardial infarction or coronary disease (epicardial coronary lesions
> 50%), previous mitral valve intervention, active endocarditis, mitral
stenosis, congenital heart disease, cardiomyopathy, or refusal of patient
consent. A total of 1705 patients met the enrollment criteria and were
analyzed in the present study.
The patients were stratified according to the presence or absence of
early postoperative LV dysfunction, defined as an LVEF < 50% on
predismissal echocardiographic assessment.10,12The Journal of Thoracic and CarData Collection
Patient demographics, medical and surgical history, baseline cardiac
status, and perioperative data were derived from the Mayo Clinic’s
Division of Cardiovascular Surgery’s electronic patient database and by
manual review of the patient medical records. Follow-up data and vital
status were obtained from review of the medical records from our
institution and outside centers, formal health assessment questionnaires
sent to patients and next-of-kin, and the Social Security Death Index.
Echocardiographic Analysis
All patients underwent transthoracic echocardiographic evaluation
before and after mitral valve repair surgery. Echocardiographic imaging
was performed at a median of 20 days preoperatively and 4 days
postoperatively. Postoperative echocardiography is performed routinely
before dismissal at our institution to re-evaluate valve and cardiac
function and to rule out postoperative complications. At postoperative
echocardiography, the patients were not receiving inotropic support.
Echocardiographic studies were performed according to routine clinical
practice. Two-dimensional direct measurements from parasternal long-axis
views orM-mode echocardiographywere used to obtain LVmeasurements.
EF was obtained using differences in ventricular dimensions. The postop-
erative degree of MR was assessed semiquantitatively using scales ranging
from 1 to 4 by Doppler echocardiography dictated by the American Society
of Echocardiography.13 A diagnosis of flail segment was made based on
failure of leaflet coaptation, with rapid systolic movement of the affected
leaflet tips toward the left atrium. Patients with features consistent with
other diseases such as ischemic mitral regurgitation, functional, or
nonprolapsing segments were excluded.
We analyzed the long-term postoperative changes in several key
variables, including the LVEF, LV diameters (LV end-diastolic diameter,
LVESD), and left atrial size, within the groups of patients with a
postoperative LVEF of<50% and LVEF of 50% and compared these
changes between the 2 groups.
Surgical Procedure
Mitral valve repair was performed through a partial or full sternotomy
or using a minimally invasive approach (ie, port access/right lateral
thoracotomy or robot-assisted technique). Valve repair was performed with a
variety of surgical techniques used at Mayo Clinic. For posterior leaflet
prolapse, triangular leaflet resection is typically performed. Anterior leaflet
prolapse is commonly corrected using Gore-Tex artificial neochordal replace-
ment (expanded polytetrafluoroethylene, Gore-Tex; W.L. Gore & Associates,
Inc, Flagstaff, Ariz). Mitral valve annuloplasty is typically performed using a
standard length flexible posterior band (63 mm) anchored with interrupted
Ethibond stitches between the left and right fibrous trigones.14-16Statistical Analysis
Categorical variables are reported as the frequency and percentage and
continuous variables as the mean  standard deviation or median and
interquartile range, as appropriate. Categorical variables were compared
between patients with and without an early postoperative LVEF of<50%
using the chi-square test or Fisher’s exact test. Continuous variables were
compared usingStudent’s t test or theWilcoxon rank sum test, as appropriate.
Logistic regression models were used to determine the predictors of
early postoperative LV impairment. Kaplan-Meier methods were used to
estimate survival after mitral valve repair, with patients censored at last
known follow-up. Cox proportional hazards models were used to identify
univariate and multivariate predictors of long-term all-cause mortality.
Multivariate Cox models constructed using significant variables from
univariate analysis (P < .05) corresponded to models derived by
backward-and-forward stepwise methods. To examine the relationship
between postoperative LVEF as a continuous parameter and the hazard
of late death, we used penalized smoothing splines.17 Finally, we identifieddiovascular Surgery c Volume 148, Number 6 2753
TABLE 1. Baseline characteristics
Variable
Predismissal LVEF
P valueAll patients (n ¼ 1705) 50% (n ¼ 1391) <50% (n ¼ 314)
Clinical characteristics
Age (y) 58.8  13.1 59  12.8 57.7  14 .18
Atrial fibrillation 105 (6.2) 80 (5.7) 25 (7.9) .14
BMI (kg/m2) 25.9  4.3 26  4.2 25.5  4.6 .002
BSA (m2) 1.93  0.23 1.93  0.23 1.94  0.24 .95
COPD 108 (6.3) 84 (6.1) 24 (7.7) .29
Diabetes 45 (2.6) 38 (2.7) 7 (2.2) .61
Female sex 575 (34) 487 (35) 88 (28) .018
Hypertension 693 (40.7) 589 (42.4) 104 (33.2) .003
NYHA class III or IV 496 (29.2) 393 (26.3) 103 (32.9) .11
Peripheral vascular disease 68 (3.9) 52 (3.7) 14 (4.4) .54
Renal failure (creatinine>1.4 mg/dL) 10 (0.9) 8 (0.9) 2 (1) .88
Stroke 29 (2.5) 23 (2.4) 6 (2.9) .72
Surgical characteristics
Artificial chordae implant 261 (15.2) 211 (15.2) 50 (15.9) .73
ECC (min) 60  30 61  31 59  28 .44
Interatrial communication 267 (15.6) 222 (16.3) 45 (14.3) .38
Leaflet plication 331 (19.4) 259 (18.6) 72 (22.9) .08
Maze procedure 178 (10.4) 145 (10.4) 33 (10.5) .96
Robotic MV repair 262 (15.4) 213 (15.3) 49 (15.6) .81
Surgical era (2003-2012) 1073 (62.9) 884 (63.5) 189 (60.2) .26
Triangular resection 1116 (65.5) 902 (64.8) 214 (68.2) .26
TV repair 77 (4.5) 64 (4.6) 13 (4.1) .72
Aortic crossclamp time (min) 43  22 43  22 42  21 .43
Data presented as n (%) or mean  standard deviation. LVEF, Left ventricular ejection fraction; BMI, body mass index; BSA, body surface area; COPD, chronic obstructive
pulmonary disease; NYHA, New York Heart Association; ECC, extracorporeal circulation; MV, mitral valve; TV, tricuspid valve.
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Dthe threshold values of LVESD and right ventricular systolic pressure
(RVSP) that offered the greatest discriminatory power in predicting the
development of early postoperative LVEF of<40%. All statistical tests
were 2-sided, with the a level set at 0.05 for statistical significance.
Analyses were performed using Statistical Analysis Systems, version
9.13, software (SAS institute, Inc, Cary, NC).
RESULTS
Baseline Clinical Characteristics
All patients had a preoperative LVEF> 60% on the
preoperative echocardiogram. The baseline characteristics
for all patients and those stratified by the presence or
absence of postoperative LV dysfunction (EF< 50%) are
presented in Table 1. The overall mean age was 59  13
years, and 575 of the patients were women (34%). Of the
1705 patients with preserved LVEF before surgery, 314
(18.4%) developed systolic dysfunction (LVEF< 50%)
after mitral valve repair. With the exception of a lower
prevalence of women (28% vs 35%; P¼ .018) and patients
with hypertension (33% vs 42%; P ¼ .003) in those with
LV dysfunction, all other baseline and operative variables
were comparable between the 2 groups. No differences
were found in the surgical techniques used or the ischemic
or cardiopulmonary bypass times between those with and
without early postoperative LV dysfunction.
To further understand the fate of a subgroup of patients
without guideline-based class I or IIA triggers for mitral2754 The Journal of Thoracic and Cardiovascular Survalve surgery, we identified and analyzed those 585
(34%) asymptomatic patients with normal preoperative
LV function and LVESD< 40 mm, who were also free
from atrial fibrillation and pulmonary hypertension
(RVSP < 50 mm Hg) at baseline surgery. Of these,
68 patients had evidence of early postmitral valve
repair LV dysfunction (EF < 50%) on predismissal
echocardiography—representative of 22% of this
‘‘trigger-free’’ subgroup (68 of 314 with LVEF<50%).
Early Postoperative Clinical Outcomes
The postoperative clinical course of all patients and those
stratified according to postoperative LVEF are outlined in
Table 2. Overall, a total of 4 early deaths (0.2%) occurred,
with no difference in mortality between patients with and
without early postoperative LVEF < 50% (0.14% vs
0.64%; P ¼ .10). As expected, patients with early LV
dysfunctionmore frequently required postoperative inotropic
support (28.0% vs 37.3%, P ¼ .04), although this did not
correlate with a prolonged intensive care unit or hospital stay.
Early Changes in Echocardiographic Parameters
Changes in LVEF, LV dimensions, and pulmonary artery
pressure between preoperative and early postoperative
assessments were examined and stratified according to the
presence or absence of early postoperative LV dysfunctiongery c December 2014
TABLE 2. Comparison of postoperative clinical course stratified by
early predismissal LVEF
Variable
EF
P
value
50%
(n ¼ 1391)
<50%
(n ¼ 314)
Hospital LOS (d) 5 (4-7) 5 (4-7) .37
IABP 10 (0.7) 3 (0.9) .66
ICU stay (h) 22.5 (18.5-22.5) 23 (18.8-26.5) .11
Infection (all) 47 (3.4) 6 (1.9) .17
Need for inotropic support 136 (28) 50 (37.3) .04
Renal failure 7 (0.5) 4 (1.2) .12
Reoperation for bleeding 32 (2.3) 12 (3.8) .12
Residual moderate or more MR 33 (2.4) 5 (1.5) .35
Stroke 6 (0.4) 1 (0.3) .78
Data presented as median (interquartile range) or n (%). EF, Ejection fraction;
LOS, length of stay; IABP, intra-aortic balloon pump; ICU, intensive care unit;
MR, mitral regurgitation.
FIGURE 1. Change in left ventricular (LV) end-diastolic diameter
(LVEDD) and LV end-systolic diameter (LVESD) between preoperative
and early postoperative echocardiograms. Top, Among patients
without postoperative LV impairment (ejection fraction [EF]
 50%), (A) LVEDD and (B) LVESD declined after mitral valve
repair. Bottom, In those with postoperative LV dysfunction
(EF< 50%), (C) LVEDD decreased and (D) LVESD increased after
surgical valve repair.
Quintana et al Acquired Cardiovascular Disease(Table 3 and Figure 1). As expected, patients with a
postoperative EF of<50% experienced a greater decline
in EF than did those without LV impairment (EF  50%,
7.6% vs EF < 50%, 23.5%; P < .001). Although
changes in LV end-diastolic diameter were comparable
between groups (EF  50%, 6.8 mm [11.8%] vs
EF<50%, 6.6 mm [10.7%]; P ¼ .54), early postoper-
ative LV dysfunction coincided with a significant
enlargement in LVESD (EF  50%, 0.6 mm [1.7%]
vs EF < 50%, þ4.3 mm [þ11.4%]; P < .001) and
decrease in pulmonary artery pressure (RVSP, EF
 50%, 2.7 [7.1%] vs EF< 50%, 7.8 [18.1%];
P<.001).TABLE 3. Comparison of pre- and postoperative echocardiographic
data
Variable
EF
P value50% (n ¼ 1391) <50% (n ¼ 314)
LVEF (%)
Preoperatively 66.8  4.8 (66) 65.3  4.0 (65) <.001
Postoperatively 59.2  5.8 (60) 41.8  6.2 (45) <.001
Change 7.6  6.8 (8) 23.5  7.3 (22) <.001
LVEDD (mm)
Preoperatively 57.3  5.9 (57) 61.8  5.9 (62) <.001
Postoperatively 50.3  5.7 (50) 54.6  6.1 (55) <.001
Change 6.8  5.1 (7) 6.6  4.7 (6) .54
LVESD (mm)
Preoperatively 34.2  4.6 (34) 37.7  4.4 (38) <.001
Postoperatively 33.4  5.1 (33) 41.9  5.4 (42) <.001
Change 0.6  4.2 (1) 4.3  4.5 (6) <.001
RVSP (mm Hg)
Preoperatively 38  13.2 (34) 43.2  16.7 (39) <.001
Postoperatively 35.3  9.6 (34) 35.5  9.4 (34) .62
Change 2.7  12.6 (1.8) 7.8  15.9 (5) <.001
Data presented as mean  standard deviation (median). LVEF, Left ventricular ejec-
tion fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
end-systolic diameter; RVSP, right ventricular systolic pressure; EF, ejection fraction.
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DLong-Term Evolution of LV Size and Function
Early postoperative LV dysfunction identified imme-
diately after mitral valve repair was found to persist
during longitudinal echocardiographic follow-up. Five
years after index repair, EF had recovered to preoperative
levels of>60% in only 31.5% of the patients with early
postoperative LV dysfunction (EF<50%) compared with
65.9% of those without early LV dysfunction (EF 
50%; P< .001; Figure 2, A). Specifically, EF remained
significantly lower in the early dysfunction group, while
both the LV end-diastolic diameter and the LVESD were
higher up to 10 years following mitral valve repair
(Figure 2, B).
Predictors of Early EF<50%
In an effort to identify factors predisposing patients
with preoperative EF > 60% to the development of
early postoperative LV impairment after mitral valve repair,
we further studied the predictors of postoperative
LVEF< 50% (Table 4). After adjustment for influential
covariates in multivariable logistic regression analysis, a
larger preoperative LVESD (odds ratio [OR], 1.2 per 1
mm; 95% confidence interval [CI], 1.14-1.24; P< .001)
and higher RVSP (OR, 1.03 per 1 mm Hg; 95% CI,
1.02-1.04; P < .001) were independent predictors of
postoperative LV dysfunction.diovascular Surgery c Volume 148, Number 6 2755
FIGURE 2. Evolution of echocardiographic data during follow-up compared in both groups according to early postoperative left ventricular ejection
fraction (LVEF)<50% or50% at different time points after mitral valve repair. Comparison of (A) LVEF and (B) left ventricular end-diastolic diameter
(LVEDD) (black) and left ventricular end-systolic diameter (LVESD) (gray).
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DLate Reoperation
Freedom from reoperation at 5 and 10 years was 96.7%
and 93.8%, respectively. A total of 54 patients (3.4%)
required a second operation on the mitral valve at a
mean of 5 years after the initial repair, corresponding to a
linearized rate of reoperation of 0.1% per year. In 19
patients (35%), the valve was re-repaired, and 35 (65%)
underwent prosthetic valve replacement. The reasons for
reoperation included MR recurrence in 50 patients, systolic
anterior motion in 1, and mitral valve endocarditis in 3. No
differences were seen in the reoperation rate between
patients with versus without postoperative LV dysfunction
(EF<50%; P ¼ .37).Long-Term Survival
The data on long-term survival were 93% complete. The
mean  standard deviation follow-up was 5.9  5.2 yearsTABLE 4. Preoperative predictors of early postoperative LV
dysfunction (EF<50%)
Preoperative
data
Univariate
analysis
P value
Multivariate
model P
valueOR (95% CI) OR (95% CI)
Female sex 0.72 (0.55-0.95) .018
Hypertension 0.68 (0.52-0.87) .002
Greater LVEF 0.93 (0.9-0.95) <.001
Greater LVEDD 1.14 (1.11-1.16) <.001
Greater LVESD 1.18 (1.14-1.23) <.001 1.2 (1.14-1.24) <.001
Greater LAD 1.05 (1.02-1.08) <.001
Greater LV mass 1.01 (1-1.01) <.001
Greater ERO
(PISA)
3.52 (2.15-5.76) <.001
Greater RVSP 1.02 (1.01-1.03) <.001 1.03 (1.02-1.04) <.001
LV, Left ventricular; OR, odds ratio; CI, confidence interval; LVEF, left ventricular
ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD; left
ventricular end-systolic diameter; LAD, left atrial diameter; ERO, effective
regurgitant orifice; PISA, proximal isovelocity surface area; RVSP, right ventricular
systolic pressure.
2756 The Journal of Thoracic and Cardiovascular Sur(maximum, 20.2). A total of 170 patients (9.9%) died
during the follow-up period at a mean age of 78 years.
Overall survival for all patients was 95%, 85%, and
70.8% at 5, 10, and 15 years, respectively. When consid-
ering late outcomes in patients with early postoperative
EF 50% versus<50%, survival was comparable between
the groups at all measurement points (5 years, 96% vs 95%;
10 years, 89% vs 86%; 15 years, 79% vs 73%; P ¼ .65).
To further evaluate the relationship between the differing
severities of early postoperative LV dysfunction and late
mortality, we generated spline functions, studying the
predismissal EF as a continuous variable (Figure 3). We
found that progressively poorer early postoperative EF
correlated with an increased hazard of late death. In
particular, late survival was significantly less in patients
with a postoperative EF < 40% (n ¼ 71) at dismissal
from hospital compared with those with an LVEF of
40% (n ¼ 1634; 5 year, 96% vs 93%; 10 years, 87%
vs 75%; 15 years, 75% vs 61%; P ¼ .008; Figure 4).
Understanding that more severe degrees of early
postoperative LV dysfunction were influential, we further
studied the univariate and multivariate predictors of late
all-causemortality. After controlling for the confounding ef-
fects of older age (hazard ratio [HR], 1.1; 95%CI, 1.07-1.1;
P < .001), hypertension (HR, 1.4; 95% CI, 1.0-1.8;
P ¼ .036), New York Heart Association class III or IV
(HR, 1.7; 95%CI, 1.2-2.3;P<.001), and preoperative atrial
fibrillation (HR, 2.3; 95% CI, 1.3-4.2; P ¼ .005), an early
postoperative LVEF of<40% was associated with a 70%
increase in the risk of late postoperative mortality (HR,
1.7; 95% CI, 1.03-2.92; P ¼ .037; Table 5).Predictors of Early Postoperative EF<40%
Having identified an EF of <40% as a potentially
important threshold for an increased hazard of late death,
we modeled the preoperative determinants of developing
this degree of postoperative LV dysfunction immediatelygery c December 2014
TABLE 5. Univariate and multivariate predictors of all-cause long-term mortality
Preoperative data
Univariate analysis
P value
Multivariate model
P valueOR (95% CI) OR (95% CI)
Age 1.10 (1.08-1.11) <.001 1.09 (1.07-1.11) <.001
Female sex 1.32 (0.97-1.79) .074
Diabetes 1.55 (0.64-3.77) .337
Hypertension 1.78 (1.32-2.40) <.001 1.38 (1.02-1.87) .036
NYHA class III-IV 2.58 (1.89-3.53) <.001 1.71 (1.25-2.35) .001
Preoperative atrial fibrillation 4.88 (2.75-8.65) <.001 2.33 (1.39-4.19) .005
ECC (min) 1.00 (1.00-1.01) .078
Aortic crossclamp time (min) 1.00 (1.00-1.01) .473
TV repair 3.75 (2.26-6.20) <.001
Maze procedure 1.75 (1.11-2.77) .017
Preoperative RVSP (mm Hg) 1.03 (1.02-1.04) <.001
LAD (mm) 1.03 (1.01-1.05) .006
Preoperative LVESD 0.99 (0.93-1.06) .824
Preoperative LVEDD 0.99 (0.95-1.04) .780
Preoperative MR ERO 0.44 (0.20-0.96) .038
Preoperative LV mass 1.00 (1.00-1.00) .337
Preoperative RVSP  38 mm Hg 2.94 (1.93-4.48) <.001
Postoperative LVEF<40% 1.99 (1.19-3.33) .009 1.74 (1.03-2.92) .037
OR, Odds ratio; CI, confidence interval; NYHA, New York Heart Association; ECC, extracorporeal circulation; TV, tricuspid valve; RVSP, right ventricular systolic pressure;
LAD, left atrial diameter; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; MR ERO, mitral regurgitation effective regurgitant
orifice; LVEF, left ventricular ejection fraction; LV, left ventricular.
Quintana et al Acquired Cardiovascular Diseaseafter mitral valve repair. Using multivariable logistic
regression analyses, we were able to establish that a larger
preoperative LVESD and greater preoperative RVSP were
both influential (P < .001 for both). Through multiple
logistic regression analyses, we identified thresholds of
LVESD> 36 mm and RVSP> 49 as having the greatest
discriminatory power in predicting a postoperative EF of
<40% (Table 6).A
C
DDISCUSSION
We studied early postoperative LV impairment in a
homogeneous population of patients with severe degenerativeFIGURE 3. Relationship between early ejection fraction (EF) after mitral
valve repair and hazard of late death. Hazard ratio and 95% confidence
intervals (dotted lines) for the risk of overall mortality, with the left
ventricular EF represented as a spline function. Lower postoperative EF
was associated with a greater late risk of late death.
The Journal of Thoracic and CarMRand preserved LV function (EF>60%) undergoingmitral
valve repair. We found that approximately 1 in 5 patients
developedearlyLVdysfunction (EF<50%).Of thesepatients,
one fifth were free of typical class I or IIA indications prior to
surgery. Importantly and contrary to the current perception,
only 1 in 3 patients with postoperative LV impairment
experience recovery of EF to preoperative levels at 5 years
after valve repair. Although an EF threshold of<50% on
predismissal echocardiogram did not appear to affect late
survival in the present analysis, leaving the hospital with an
EF of<40% did independently predict a 70% increase in
the hazard of late death. Moreover, we have demonstrated
that a preoperative RVSP > 49 mm Hg and LVESDFIGURE 4. Comparison of overall long-term survival stratified by early
left ventricular dysfunction (threshold left ventricular ejection fraction
[EF]<40%).
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TABLE 6. Preoperative predictors of early postoperative LVEF<40%
Preoperative data
Univariate analysis
P value
Multivariate model
P valueOR (95% CI) OR (95% CI)
Greater LV mass 1.01 (1.01-1.01) <.001
Greater LAD 1.07 (1.03-1.11) <.001
Greater LVEDD 1.19 (1.14-1.25) <.001
NYHA class III or IV 1.94 (1.2-3.14) .007
Atrial fibrillation 2.66 (1.32-5.35) .006
RVSP>49 mm Hg 4.57 (2.54-8.23) <.001 4.40 (2.35-8.23) <.001
Higher ERO (PISA) 5.00 (2.4-10.4) <.001
LVESD>36 mm Hg 5.93 (3.15-11.97) <.001 6.46 (3.31-13.61) <.001
OR, Odds ratio; CI, confidence interval; LV, left ventricular; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association;
RVSP, right ventricular systolic pressure; ERO, effective regurgitant orifice; PISA, proximal isovelocity surface area; LVESD, left ventricular end systolic diameter.
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D>36 mm are associated with a 4.4- and 6.5-fold increased risk
of developing early postoperative LVEF<40%, respectively.
Collectively, these data suggest that caution must be exercised
during ‘‘watchful waiting’’ for patients with severe MR based
on the false reassurance of ‘‘preserved’’ preoperative LVEF
alone.
As has been demonstrated in previous studies,10 we
observed a decline in LVEF after surgical correction of MR.
It was somewhat surprising, however, that this decrease was
also identified in a heretofore ‘‘understudied’’ population
with ‘‘preserved’’ preoperative myocardial function.
Although an early postoperative decrease in EF between
5% to 10% in the nonimpaired ventricle after mitral repair
can be explained as a volumetric adjustment to the elimina-
tion of the proportion of total ventricular ejection contributing
to regurgitation,5,8 greater postoperative decreases in EF have
been associated with the markers of degenerative MR
chronicity, including myocardial fibrosis, hypertrophy, and
adverse remodeling.8,18-20 Although tempting to impugn
surgical intervention as the cause of the deterioration, it is
noteworthy that the surgical techniques and operative
durations were indistinguishable between the groups with
and without early dysfunction, indicating that the
myocardial predisposition for LV deterioration was present
before the intervention. Importantly, in our present series,
patients in both groups had a clinically similar (although
statistically different) preoperative EF (66.8% vs 65.3%,
P< .001), cautioning against reliance on this nonspecific
trigger in determining the extent of myocardial impairment
and timing of surgical intervention. The degree of
preoperative left-sided heart chamber enlargement appeared
influential, as previously reported.8 Pulmonary hypertension
in patients with MR even in the setting of a ‘‘preserved’’ EF
is a frequent finding21 that can persist even after repair.22
In agreement with Varghese and colleagues,10 we found
that greater degrees of pulmonary hypertension were
associated with poorer early postoperative EF. Our study
differed, however, in that we focused on a population of
patients without ischemic burden and with a preoperative
EF>60%.2758 The Journal of Thoracic and Cardiovascular SurIn our present report, LV function returned to normal
levels (>60%) in only one third of the patients with an early
postoperative EF<50% compared with two thirds of those
without ventricular impairment after surgery; thereby,
dispelling the commonly held notion that EF ‘‘always’’
recovers after successful elimination of MR. Despite
chordal preservation and short crossclamp times, markers
of increased MR chronicity preoperatively were associated
with impaired long-term capacity for reverse LV remodel-
ing. Eccentric myocardial hypertrophy, fibrosis,23 and in-
flammatory cascades could all potentially be associated
with this phenomenon and can only be prevented by
mechanical elimination of MR after successful mitral valve
repair.
The historic work of Crawford and colleagues11
identified an EF< 50% after surgical correction of MR
as deleterious to long-term survival. That series included
mixed etiologies of mitral valve disease (eg, ischemic,
rheumatic) and those undergoing valve replacement. We
have identified, for the first time to our knowledge, that
more severe postrepair LV dysfunction (EF<40%) could
be a potent adverse prognostic marker in patients with
isolated degenerative MR and, further, that an LVESD
> 36 mm24 and an RVSP > 49 mm Hg are important
predictors of encountering this degree of impairment after
degenerative mitral valve repair. Even after controlling for
potential confounders, an EF < 40% at dismissal from
hospital after mitral valve repair independently predicted
a 70% increase in late mortality risk. This important finding
cautions against the reassurance of patients that watchful
waiting is safe in the presence of preserved ventricular
function and severe degenerative MR.
An increasing body of clinical comparative effectiveness
data supports the favorable long-term survival and
diminished heart failure risk associated with earlier
surgical intervention in patients with severe degenerative
MR.2,20,28,29 The argument for the earlier referral of
asymptomatic patients with severe degenerative MR in
the absence of classic guideline-based triggers hinges,
however, on the provision of a valve repair likelihood ofgery c December 2014
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D>95% to 99% for all prolapse categories,16,30 with a
mortality and/or morbidity risk of <1%. The clinical
relevance of the present findings include highlighting the
need for (1) accurate echocardiographic quantification of
severe MR in all patients with a systolic murmur, (2)
participation in a data-driven discussion regarding the
timing of surgery in those with severe MR and an
EF > 60% (drawing particular attention to recent data
addressing the risk/benefit ratio of early mitral valve repair
vs watchful waiting); and (3) advising caution in delaying
mitral valve repair in the presence of an LVESD of 35 to
40 mm or RVSP of 40 to 50 mm Hg. Falsely reassuring
patients with severe MR that watchful waiting is safe on
the basis of a normal EF alone unnecessarily exposes
them to the risk of LV dysfunction and a survival disadvan-
tage when EF after MR correction is<40%.
Echocardiographically assessed LVEF is ubiquitous in
clinical practice and is deeply embedded in contemporary
guideline-based consensus statements31; however, the use
of it alone as a single modality for LV function assessment
is falsely reassuring and problematic. Which other markers
might be useful in informing the optimal timing of surgical
intervention? Although our mitral valve repair practice has
evolved to the point that most patients currently undergoing
isolated mitral valve repair for severe degenerative MR are
asymptomatic and without triggers, patients with MR
who were detected late in their disease course or sent
from outside institutions where watchful waiting was
considered to be ‘‘safe’’ were also included in the present
series. Thus, even in the 585 patients (34% of our entire
population) who were free of both class I (New York Heart
Association class III or IV symptoms, EF  60%, or
LVESD > 40 mm) and class II (atrial fibrillation or
pulmonary hypertension) triggers for intervention, 12%
(68 of 585) still developed early postoperative LV
dysfunction (LVEF < 50%). This finding emphasizes
the point that even in this ‘‘favorable’’ population who
underwent ‘‘very-early’’ mitral valve repair, chronic severe
MR could already have resulted in irreversible myocardial
damage and deleterious clinical consequences. The
capacity for nascent modalities such as myocardial strain,25
hormonal activation,26 and exercise capacity27 to better
identify those at increased risk of LV dysfunction and/or
diminished late survival is presently under investigation at
several centers worldwide. In addition to the long-term sur-
vival implications, the clinical importance of identifying
those with limited potential for myocardial recovery lies
in facilitating both the initiation of aggressive medical
therapy and also increased frequency of clinical and
echocardiographic surveillance.
Study Limitations
The present study was subject to the limitations inherent
in a nonrandomized observational series. The patients inThe Journal of Thoracic and Carthe present study were necessarily selected because of
their willingness and availability to undergo clinical and
echocardiographic surveillance. We were unable to obtain
follow-up echocardiograms for each and every patient in
our population encompassing a surgical experience
spanning>2 decades. Additionally, owing to the particular
referral pattern in our practice, accurate tracking of death in
patients from foreign countries was limited by laws regu-
lating the release of death certificates. Despite widespread
availability of echocardiography as a guideline-sanctioned
measure of LV function, the technology is limited in its
ability to detect latent LV dysfunction. Future studies
using exercise-induced myocardial strain assessment and
magnetic resonance imaging will be informative.CONCLUSIONS
Although mitral valve repair for degenerative disease
can be performed with very low mortality in patients with
‘‘normal’’ preoperative EF, early postoperative LV
dysfunction is not uncommon. Importantly, early myocar-
dial impairment might be irreversible and associated with
increased long-term mortality risk. A preserved preopera-
tive EF > 60% should, therefore, not provide false
reassurance of the maintained capacity for restoration of
LV function or normalization of survival when mitral valve
repair is delayed. These data indicate that surgical interven-
tion before the onset of excessive LV dilation, pulmonary
hypertension, or symptoms appears warranted.
The authors wish to thank Judy Lenoch for assistance in data
retrieval and David Hodge for the statistical assessment.References
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Dr David H. Adams (New York, NY). Rakesh, I really enjoyed
this presentation and your leadership in the field. So much of the
evidence base that serves as a foundation for the American
College of Cardiology/American Heart Association (ACC/AHA)
guidelines have originated from the Mayo experience, and your
new data are provocative and will have implications for future
guidelines. Let us explore a few details.
My first question is, what led you to focus on patients with an
EF> 60% instead of all-comers, given that the surgical trigger
point around 60% has been an established criterion in the
ACC/AHA guidelines for the past several years based on historical
data from the Mayo? I imagine there was some curiosity among
your colleagues about this study in the first place, because these
results could well redefine what we have held true for the past
few decades.
Dr Suri. Thank you, Dr Adams, and we would like to
acknowledge your international leadership and contributions to
this field.
You make an important point, and that is, why should we
consider operating in advance of established guidelines?
Comparative effectiveness research recently published,
including the Mitral Regurgitation International DAtabase
(MIDA) analysis late last year and the study by Kang and
colleagues several weeks ago, both point us in the direction of
understanding to a greater degree the ability of early mitral valve
repair—which is low risk and associated with low morbidity in the
modern era—to improve late outcomes. This is true, in terms of
both enhanced late survival and freedom from heart failure
many years after early mitral valve repair. A growing population
of patients thus present to us at Mayo Clinic without the
typical class I or IIA triggers for operation and elect to undergo
early correction of severe degenerative MR, cognizant of
these benefits. Most, if not all, of these patients, have a ‘‘normal’’
preoperative EF.
But what struck us in this particular population of patients was
that, despite having what was thought to be ‘‘normal’’ ventricular
function before surgery, a proportion of these patients develop
profound LV dysfunction immediately after separation from
cardiopulmonary bypass. Typically, these individuals require
inotropic support for a couple of days and leave the hospital
with an EF of<50%. The first question that many have asked is,
‘‘What happened during the operation?’’
Well, we went back to our operative notes and found no
important technical differences in the course of the operation.
These are often patients who have 20- or 30-minute crossclamp
times and successful mitral valve repair operations with none-to-
trivial residual MR, yet they developed LV dysfunction. This led
us to ask ‘‘why’’ and ‘‘when’’ and to further investigate thisgery c December 2014
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Dheretofore understudied population of patients.
Dr Adams. It is a point Carpentier made, and it is so relevant to
all of us. Often, our patient experience triggers our trying to answer
a question.
My next point is about the current guidelines for the
end-systolic diameter of 40 mm and the estimated pulmonary
artery pressure of 55 mm Hg as the cutoff for decision-making
for surgical intervention. Why did you choose the trigger levels
you highlighted today? How did you settle on the end-systolic
diameter of 36 mm, for example, as a potential trigger instead of
another number?
Dr Suri. Thank you. That is a very good question. As those in the
room know who have worked to identify cutpoints, it is a very sta-
tistically ‘‘intensive’’ process. I can summarize by saying we
worked closely with our statisticians to construct multiple logistic
regression analyses and identified threshold values of LVESD
and RVSP that predicted the development of postoperative LVEF
<40% with the greatest discriminatory power. We assessed this us-
ing the areas under the receiver operating characteristic curves.
The next point to emphasize is that these are not magical
numbers or cutpoints. We do not imagine they will necessarily be
embedded into future iterations of the recommendations guiding
treatment of all patients with degenerative MR. However, we can
state that these thresholds appear influential in predicting postoper-
ative LV dysfunction specifically in the present population we stud-
ied with an EF>60% on the preoperative echocardiogram. These
results will hopefully prompt initiation of the next generation of
clinical trials to further study advanced indications for the perfor-
mance of mitral valve repair, specifically in patients with echocar-
diographically documented severe MR by proximal isovelocity
surface area measurements.
Dr Adams. Let us continue on that theme and talk about
additive value now. Can you tell us whether you examined the
outcomes of patients who had the combination of an elevated
end-systolic diameter of 36 mm and pulmonary pressure of 45
mm Hg? A few years ago, Triboully and colleagues emphasized
the additive value of near trigger points, not exceeding one
but just near trigger points, and I wonder if you have done this
exploratory analysis?
Dr Suri. That is a very good question, and I would say the
results of the present study have piqued our interest in pursuing
additional subset analyses. Just ‘‘back-of-napkin’’ calculations,
we have combined those 2 trigger points—LVESD > 36 mm
and RVSP> 49 mm Hg—and arrived at an odds ratio that was
greater in conjunction than for each of them separately. We
estimated an approximately eightfold greater risk of developing
postoperative LVEF< 40% when both of those trigger points
were observed prior to mitral valve repair.
Dr Adams. This is really important, because we need to move
away from single-number triggers and start thinking about the com-
bination and your trigger points, and I expect when you do that anal-
ysis, we might be even lower than 36 or 45 in combination.
My next point is about your bypass times, which you mentioned
were extremely short. I find that actually very sobering, in
particular, as the guidelines are moving us toward asymptomatic
intervention in class IIA indications. Do you have any thoughts
about that in terms of why this is happening or what we need to
learn for the future?The Journal of Thoracic and CarDr Suri. That is a great question. As I mentioned previously,
once a patient with asymptomatic MR leaves the operating room
with no MR but with an EF that is 40%, the first question that
people ask the surgeon is, ‘‘What happened, how long was the
crossclamp time?’’ Well, what struck us was that the crossclamp
and bypass times were not different between those with and
without postoperative LV dysfunction. In other words, the
predisposition for LV dysfunction was set before the performance
of mitral valve repair, and that is something we all need to
recognize and investigate further.
Dr Adams.My last comment is about the clinical implications
of your results for our daily practice. Your thoughts about strain,
other analyses of the ventricle outside of the ejection fraction?
Finally, how are you currently treating patients with a lower EF
after mitral valve repair for degenerative disease?
Thank you again for this provocative analysis.
Dr Suri. Thank you, Dr Adams. To be very quick with the
response for the sake of time, the next wave of prognostic
markers that will be investigated to help advance our understanding
of the pathophysiologic consequences of severe chronic degenera-
tive MR will include assessment of brain natriuretic peptide, exer-
cise testing, LV strain, and left atrial chamber size. We, and others
around theworld, are currently investigating the sensitivity and spec-
ificity of these modalities in attempting to elucidate the ideal timing
of mitral valve repair in asymptomatic patients in advance of the
onset of guideline-based triggers.
What do we do when we document LV dysfunction on the
predismissal echocardiogram? Dr Schaff, myself, and my
colleagues at Mayo Clinic, when we are faced with a patient
who has an EF< 50% after mitral valve repair, we generally
institute angiotensin converting enzyme inhibitor therapy at
dismissal. We also consider those patients candidates for
increased intensity of medical and echocardiographic surveillance
when they return to their home community.
Upon discovery of profound postoperative dysfunction, an EF
of<40%, after mitral valve repair in a patient with a previously
normal EF, we consider involving our heart failure colleagues
before dismissal from the hospital, because we believe these
patients should be monitored with even greater frequency.
Dr Niv Ad (Falls Church, Va). Rakesh, I enjoyed your
presentation. I think, on the same line, it is important to understand
what your definition of a successful repair is, because we all know
that leaving the operating room without MR is not always enough.
Also, what happened to the patient who died earlier or had a
greater mortality rate with regard to their mitral repair status?
Was the successful repair stable throughout the study or did you
have grade 2 MR in this group that died?
Dr Suri. There was 0.2% mortality in this population, so 4
deaths in the whole study. It was very low.
To the point about what constitutes a successful repair, at Mayo
Clinic, we rely on our echocardiographic assessment, separating
from cardiopulmonary bypass with trivial-to-mild or less MR,
and a gradient that is<3, typically. Is that what you mean?
Dr Ad. We all know that leaving the operating without MR is
not necessarily enough, and it is not definitely reflective of the
long-term success of the mitral valve repair.
Dr Suri. So echocardiographic predictors?
Dr Ad. Yes.diovascular Surgery c Volume 148, Number 6 2761
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the echocardiogram, such as coaptation depth, and confirm smooth
nonturbulent outflow, the absence of systolic anterior motion, and
the absence of regional wall motion abnormalities.
Those are the typical things. Is that what you are getting at?
Dr del Nido. We are going to have to keep going with this
discussion. Perhaps they can continue afterward. One more very
short question, please.
Dr Mohamed Emara (Cairo, Egypt). I congratulate you for
this nice presentation. Did you try the end-systolic phase indexes
rather than the ejection phase indexes? As we all know, in chronic
volume overload, when a leak is present in the mitral valve, EF is
usually higher than normal, so one might start with the wrong
judge on the ventricle.
Dr Suri. Sorry, did we consider other modalities?2762 The Journal of Thoracic and Cardiovascular SurDr Emara. No, other indexes to evaluate the left ventricle. You
used the ejection phase indexes.
Dr Suri. It is a very good point. We have to remember 1
critical thing, and when we were writing the report we spoke
about this several times. That is, although we might all use a
varied and heterogeneous array of modalities to assess LV
function in research studies, the reality is that echocardio-
graphic assessment of LV systolic function using EF is ubiq-
uitous in current clinical practice and deeply embedded in
current clinical practice guidelines. Thus, although we can
endeavor to explore different experimental means of assessing
contractility and latent dysfunction, the truth is we did not
examine in the present study in order to permit our findings
to be generalized in the broader international clinical
community.gery c December 2014
